ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer - EurekAlert

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer  EurekAlert

Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...